The nuclear factor-κB (NFκB) family of transcription factors has been implicated in inflammatory disorders, viral infections, and cancer. Most of the drugs that inhibit NFκB show significant side effects, possibly due to sustained NFκB suppression. Drugs affecting induced, but not basal, NFκB activity may have the potential to provide therapeutic benefit without associated toxicity. NFκB activation by stress-inducible cell cycle inhibitor p21 was shown to be mediated by a p21-stimulated transcription-regulating kinase CDK8. CDK8 and its paralog CDK19, associated with the transcriptional Mediator complex, act as coregulators of several transcription factors implicated in cancer; CDK8/19 inhibitors are entering clinical development.
Here we show that CDK8/19 inhibition by different small-molecule kinase inhibitors or shRNAs suppresses the elongation of NFκB-induced transcription when such transcription is activated by p21-independent canonical inducers, such as TNFα. On NFκB activation, CDK8/19 are corecruited with NFκB to the promoters of the responsive genes. Inhibition of CDK8/19 kinase activity suppresses the RNA polymerase II C-terminal domain phosphorylation required for transcriptional elongation, in a gene-specific manner. Genes coregulated by CDK8/19 and NFκB include IL8, CXCL1, and CXCL2, which encode tumor-promoting proinflammatory cytokines. Although it suppressed newly induced NFκB-driven transcription, CDK8/19 inhibition in most cases had no effect on the basal expression of NFκB-regulated genes or promoters; the same selective regulation of newly induced transcription was observed with other transcription signals potentiated by CDK8/19. This selective role of CDK8/19 identifies these kinases as mediators of transcriptional reprogramming, a key aspect of development and differentiation as well as pathological processes.
NFκB | CDK8 | CDK19 | RNA polymerase II | regulation of transcription T he nuclear factor-κB (NFκB) family of transcription factors, comprising a variety of dimers of NFκB and Rel family proteins, has been implicated in viral infections, inflammation, and cancers (1, 2) . NFκB activation in cancers has been linked to tumor cell resistance to apoptosis and necrosis, increased proliferation, angiogenesis, and metastasis. NFκB is transiently activated by a variety of signals, including cytokines (e.g., TNFα and IL1β), chemokines, bacterial and viral products, and free radicals. Most of the inducers activate NFκB through the canonical pathway, which involves phosphorylation of NFκB-binding inhibitory IκB proteins by IκB kinases (IKKs), followed by proteasomal degradation of IκB. NFκB dimers released from IκB inhibition enter the nucleus, where they bind to specific cis-regulatory sequences in the promoters of NFκB-responsive genes, in association with coactivator proteins and RNA polymerase II (Pol II) (1) . Certain signals activate NFκB through alternative pathways, mediated by IKK or IκB proteins, such as the noncanonical pathway triggered by lymphotoxin-α that regulates a distinct class of genes.
Numerous clinical and experimental drugs have been identified as NFκB inhibitors (1, 2) , with the largest groups of such inhibitors targeting IKK or blocking proteasome activity, thereby suppressing NFκB entry into the nucleus. These NFκB-inhibiting drugs typically have significant side effects, however, possibly due to sustained NFκB suppression (1) . Drugs that would specifically affect the induced, but not the basal, NFκB activity may be able to suppress disease-promoting effects of NFκB activation without associated toxicity.
NFκB has been identified as a key factor mediating the induction of transcription of tumor-promoting cytokines and other disease-associated genes by chemotherapy-induced DNA damage (3) or by the damage-inducible cell cycle inhibitor p21 (CDKN1A) (4) . Using chemical genomics, we have developed a series of small molecules that suppress the induction of transcription by p21 or by DNA damage; the activities of these compounds include suppression of the induction of an NFκB-dependent consensus promoter by p21. These compounds were identified as selective inhibitors of two closely related cyclindependent kinases (CDKs), CDK8 and CDK19 (3). CDK8 (universally expressed) and its closely related paralog CDK19 (variably expressed) are alternative subunits of the regulatory CDK module of the transcriptional Mediator complex.
Significance
Nuclear factor-κB (NFκB) transcription factors have been implicated in several major diseases, including inflammatory disorders, viral infections, and cancer. NFκB-inhibiting drugs typically have side effects, possibly due to sustained NFκB suppression. The ability to affect induced, but not basal, NFκB activity could provide therapeutic benefit without associated toxicity. We report that the transcription-regulating kinases CDK8/19 potentiate NFκB activity, including the expression of tumor-promoting proinflammatory cytokines, by enabling the completion of NFκB-initiated transcription. CDK8/19 inhibitors suppress the induction of gene expression by NFκB or other transcription factors, but generally do not affect basal expression of the same genes. The role of CDK8/19 in newly induced transcription identifies these kinases as mediators of transcriptional reprogramming, a key aspect of development, differentiation, and pathological processes.
Unlike better-known members of the CDK family, CDK8 and CDK19 do not mediate cell cycle progression (5) . A key function of CDK8/19 is phosphorylation of the C-terminal domain (CTD) of RNA Pol II, enabling elongation of the transcription; CDK8/19 exert this activity not globally, but rather only in the context of genes that become activated by transcription-inducing factors (6) (7) (8) . CDK8/19 regulation is especially pertinent in cancers, where CDK8 positively regulates several cancer-relevant signaling pathways (5), including Wnt/β-catenin (9), the serum response network (6), TGFβ (10), HIF1α (7), and estrogen receptor (8) . CDK8 has been identified as an oncogene implicated in colorectal (9), pancreatic (11) , and breast (3, 8, 12, 13) cancers and melanomas (14) and associated with the stem cell phenotype (15) . CDK8/19 inhibition also has an antiproliferative effect in a subset of leukemias (16, 17) . Several groups are currently in the process of developing CDK8/19 inhibitors for cancer therapy applications (18) . Although a recent paper reported significant toxicity of two CDK8/19-inhibiting small molecules (19) , no toxicity has been reported in animal studies with other CDK8/19 inhibitors, including those used in the present work (3, 8, 16, 17) .
The effect of CDK8/19 inhibitors against the induction of NFκB-mediated transcription by p21 has been linked to the ability of p21 to bind CDK8 and stimulate its kinase activity (3) . However, CDK8 is also active in the absence of p21, and thus we were interested in exploring whether CDK8/19 inhibition would affect the induction of NFκB transcriptional activity by a p21-independent canonical pathway. Here we report that combining canonical pathway activators with CDK8/19 inhibitors partially suppresses transient NFκB-induced gene expression, but not basal NFκB activity. CDK8/19 inhibition has the strongest effect on induction of the IL8/CXCL1/CXCL2 cytokine family, which reportedly has key roles in chemotherapy-induced tumor-promoting activities (20) , similar to those suppressed by CDK8/19 inhibition (3). Coregulation of NFκB by CDK8/19 is exerted by elongation-enabling CTD phosphorylation of Pol II in the context of NFκB-induced genes. These results suggest the potential utility of CDK8 inhibitors in therapeutic situations involving transient NFκB activation.
Results

CDK8/19 Inhibition Suppresses NFκB Activity Induced by the Canonical
Pathway. We have previously reported that a selective smallmolecule CDK8/19 inhibitor Senexin A suppresses p21-induced activation of a consensus NFκB-dependent promoter construct driving luciferase expression in HT1080 fibrosarcoma cells (3) . In the present study, to determine whether the effect of CDK8/ 19 inhibitors on these promoters depends on p21, we measured the effect of Senexin A in the same reporter cell line, untreated or treated for 18 h with TNFα, a canonical p21-independent NFκB inducer. As shown in Fig. 1A , Senexin A had no significant effect on basal promoter activity, but inhibited TNFα-induced transcription in a concentration-dependent manner, reducing reporter activity to levels close to those seen in untreated cells. We obtained similar results in IL1R-overexpressing HEK293 cells with NFκB-stimulated E-selectin promoter driving luciferase expression (21, 22) , where NFκB was activated by a 4-h treatment with IL1 or TNFα (Fig. 1B) .
CDK8/19 Inhibition Does Not Prevent Nuclear Translocation of NFκB.
The majority of known NFκB inhibitors affect NFκB degradation in the cytoplasm or its translocation to the nucleus. While CDK8/ 19 are found only in the nucleus, they regulate the transcription of multiple genes and thus can exert their effects on NFκB either directly in the nucleus or indirectly in the cytoplasm, affecting the nuclear translocation of NFκB. We tested the effects of Senexin A on TNFα-induced nuclear translocation of p65 and p50 in HT1080 and HEK293 cells by isolating the nuclear fraction, followed by immunoblotting. As shown in Fig. 1C , TNFα stimulated the appearance of RELA (p65) and NFKB1 (p50) subunits of NFκB in the nucleus. This effect of TNFα was suppressed by TPCK (tosyl phenylalanyl chloromethyl ketone) and MG115, known to inhibit NFκB in the cytoplasm by acting on IKK or the proteasome (2). In contrast, Senexin A had no effect on TNFα-induced NFκB entry into the nucleus (Fig. 1C) . We obtained the same results using an assay measuring the binding of nuclear p65 and p50 to oligonucleotides containing NFκB-binding sites ( Fig. S1A ) and by immunofluorescence analysis of cellular localization of p65 (Fig. S1B ). Since Senexin A does not affect the nuclear translocation of NFκB, these results indicate that the effect of CDK8/19 inhibition on NFκB activity is exerted in the nucleus.
CDK8/19 Inhibition Preferentially Affects NFκB Induction of Cytokines
That Show a Strong Early Response to NFκB Activation. We performed microarray analysis of gene expression in two different sublines of HEK293, treated with TNFα or IL1 and with or without Senexin A, for different times. As shown in Fig. S2 A-C, the genes most strongly induced by TNFα or IL1 at early time points were also the genes most strongly affected by Senexin A. effects of Senexin A on the induction of these genes were similar at different concentrations of TNFα (Fig. S3A ) and were unaffected by different serum concentrations (Fig. S3B) . The effects of TNFα and Senexin A on CXCL1 expression were verified at the protein level by ELISA (Fig. S3C) . In contrast to the earlyinduced genes, genes induced by TNFα at later time points, including IL32 and TNF, were affected by Senexin A only weakly or not at all. As in the promoter assays, Senexin A had no effect on the basal expression of the majority of NFκB-regulated genes; exceptions were EGR1, JUN, and MYC, which are activated by serum factors and only weakly induced by TNFα. These genes were significantly inhibited by Senexin A in the absence of TNFα (Fig. 2) .
Both CDK8 and CDK19 Are Involved in NFκB-Induced Transcription. To verify that the effects of Senexin A are due to CDK8/19 inhibition, we compared the effects of different concentrations of Senexin A, its more potent derivative Senexin B (an early clinical stage drug candidate) (8) , and an equipotent analog of a structurally unrelated CDK8/19 kinase inhibitor, Cortistatin A (23), on the expression of CXCL1 and IL8 following the addition of TNFα to HEK293 cells. As shown in Fig. 3A , all of the compounds inhibited the induction of NFκB-responsive cytokines; the compounds' IC 50 values for this effect were proportional to their potency of CDK8/19 inhibition (Fig. 3A) .
To determine whether CDK8 and CDK19 have differential effects on NFκB activity, we used shRNA to knock down CDK8, CDK19, or both in HEK293 cells (Fig. 3B) . qPCR analysis showed that the knockdown of CDK8 or CDK19 alone partially decreased the induction of CXCL1, CXCL2, and IL8 by TNFα, as well as the effect of Senexin A on this induction, whereas both the induction and the effect of Senexin A were greatly diminished by the knockdown of both CDK8 and CDK19 (Fig. 3C) . These results indicate that both CDK8 and CDK19 are involved in NFκB-induced transcription. In contrast to HEK293 cells, which express both CDK8 and CDK19, HT1080 cells express very low levels of CDK19 (3). Partial CDK8 knockdown in an HT1080 derivative was sufficient to decrease the induction of CXCL2 and TNF by TNFα and the effect of Senexin A on this induction (Fig. 3  D and E) . Fig. 4 . As expected, TNFα treatment induced association of the p65 subunit of NFκB to the promoter regions of NFκB-responsive genes, but not of housekeeping genes. p65 recruitment was not affected by Senexin A (Fig. 4A) . On TNFα treatment, CDK8/19 [analyzed using an antibody that cross-reacts with both isoforms (24)] was corecruited with p65 to the promoter and the adjacent body regions of NFκB-responsive genes, but not of housekeeping genes. As for p65, the strongest CDK8 recruitment was associated with NFKBIA, confirming that p65 and CDK8/19 were corecruited (Fig. 4B) . Senexin A had only a minor effect on the overall TNFα-induced recruitment of CDK8/19 (Fig. 4B ). CDK9, a Pol II kinase required for the elongation of transcripts, was also recruited by TNFα treatment to the promoters and downstream regions of NFκB-regulated genes. Senexin A treatment had a small inhibitory effect on CDK9 association with these genes, most notably NFKBIA (Fig. S4A) .
Mechanism of NFκB
To analyze histone acetylation, the function of p300/CBP coactivators of NFκB, we conducted a ChIP analysis for H3K9/ 14Ac. The binding of this acetylated histone to the promoters of CXCL1 and CXCL2 was strong and unaffected by TNFα, but TNFα did increase its association with the NFKBIA promoter. H3K9/14Ac binding was unaffected by Senexin A, indicating that inhibition of CDK8/19 kinase does not affect NFκB coactivator function (Fig. S4B) .
Finally, we analyzed the effects of TNFα and Senexin A on the binding of total RNA Pol II (Fig. 4C ) and its CTDphosphorylated forms S5P (which promotes Pol II detachment from the promoter) (Fig. 4D ) and S2P (which allows the elongation of transcription) (25) (Fig. 4E) . TNFα treatment stimulated the association of all three forms of Pol II with the promoter and the bodies of NFκB-responsive genes, but not of housekeeping genes. Senexin A strongly inhibited the association of the elongation-competent S2P with gene bodies and had a weaker but still significant effect on the binding of S5P and total Pol II. This effect of Senexin B was very pronounced for the strongly CDK8/19-regulated CXCL1 and CXCL2 genes, less prominent for the weakly CDK8/19-regulated NFKBIA gene, and not observed with the housekeeping genes. Hence, the mechanism of the effect of CDK8/19 on NFκB can be described as follows: CDK8/19 are corecruited with NFκB to NFκB-responsive promoters, followed by elongation-enabling phosphorylation of Pol II CTD in an NFκB-inducible gene-specific context (Fig. 4F) . cancer cells that were untreated or treated with TNFα and Senexin B (a more potent derivative of Senexin A), individually and in combination. TNFα affected 71 genes in HEK293 and 201 genes in HCT116 cells [FDR <0.005; fold change (FC) >1.5]; >75% of these genes were induced by TNFα. Fig. 5A compares how these genes are affected by TNFα or by Senexin B in the presence of TNFα. TNFα induction of a subset of these genes was significantly diminished by Senexin B (33% of genes in HEK293 and 13% in HCT116). In both cell lines, the most strongly TNFα-induced genes tended to be those most strongly affected by Senexin B. However, only eight genes (CXCL1, CXCL2, IL8, IER3, SDC4, CD83, NFKBIA, and NFKBIZ) were coregulated by TNFα and Senexin B in both HEK293 and HCT116 cells. We asked whether p21, which stimulates CDK8 activity (3), would affect the magnitude of the effect of CDK8/19 inhibitors on NFκB-regulated transcription, using HCT116 derivatives with knockouts of p21 or its upstream regulator p53 (26, 27) . As shown in Fig. 5B , the fold induction of CXCL1, CXCL2, and IL8 by TNFα was decreased in cells with p21 or p53 knockout, but the effect of Senexin B on this induction remained the same in all three cell lines, confirming that CDK8/19 act downstream of p21 (Fig. 5B) . We also used qPCR to compare the effects of TNFα and Senexin B on CXCL1, CXCL2, and IL8 in 11 tumor and normal human cell lines, all of which induced these three genes on TNFα treatment. The effects of Senexin B were variable; in four cell lines, Senexin B inhibited the induction of all three genes by TNFα (Fig. 5C ), but in six cell lines, only IL8 induction was reduced by the CDK8/19 inhibitor, and in one cell line Senexin B augmented rather than inhibited CXCL1 and IL8 expression (Fig. S5) . Hence, while CDK8/19 inhibition suppressed NFκB-induced cytokine expression in most of the tested cell lines, these effects of CDK8/ 19 were highly cell context-dependent.
Similar variability among different cell lines was previously reported for the effects of CDK8 shRNA on hypoxia-induced HIF1A-mediated transcription (7) . We have now tested the effects of hypoxia and Senexin B treatment of HEK293 cells on four genes found in a previous study (7) to be strongly induced by hypoxia and regulated by CDK8 in HCT116. Induction of one of these genes, ANKRD37, was attenuated by Senexin B (Fig. 5D) . Notably, the CDK8/19 inhibitor affected only hypoxia-induced, and not basal, ANKRD37 expression, as we also observed for almost all of the TNFα-induced genes and promoters (Figs. 1 A and B, 2, and 5C). We also tested the effect of Senexin B on IFN γ-induced expression of STAT1 in 293 cells and found that Senexin B inhibited only IFN γ-induced, and not basal, expression of this gene (Fig. 5E ), confirming the general gene context specificity of the role of CDK8/19.
Discussion
We have found that CDK8/19 inhibition by different smallmolecule kinase inhibitors or by shRNA knockdown of both CDK8 and CDK19 inhibits the induction of transcription on NFκB activation. In contrast to almost all known NFκB inhibitors, the effect of CDK8/19 inhibition is not exerted at the level of NFκB stability, nuclear translocation, or binding of NFκB to the responsive promoters. Instead, ChIP analysis revealed that CDK8/19 is corecruited with NFκB to the promoters of NFκB-responsive genes. While CDK8/19 kinase inhibition does not affect the promoter recruitment of CDK8/19, it decreases the elongation-enabling CTD phosphorylation of Pol II at S2 and S5 and suppresses the movement of Pol II along gene bodies. This effect of CDK8/19 inhibition is specific to NFκB-induced genes and was not observed with constitutively expressed genes. The mechanism of NFκB coregulation by CDK8/19, illustrated in Fig. 4F , matches the previously elucidated mechanisms of the effect of CDK8 on the transcription induced by serum (6), HIF1A (7), or estrogen receptor (8) , indicating that Pol II CTD phosphorylation in the context of newly activated genes is the most general mechanism of transcriptional coregulation by CDK8/19. It is not the sole mechanism of regulation by CDK8/ 19, however; other CDK8/19 phosphorylation substrates also have roles in transcription-regulatory effects, such as phosphorylation of SMADs in the TGFβ pathway (10), of E2F1 (which acts as a repressor of β-catenin/TCF transcriptional activity) (28) , and of STAT1 in IFNγ-induced transcription (29) . Our data do not preclude the possibility that some other CDK8/19 phosphorylation substrates (e.g., STAT1) could complement Pol II CTD phosphorylation in NFκB coregulation by CDK8/19.
In a previous study, we reported that CDK8/19 inhibition suppressed the induction of NFκB-driven transcription by p21 (3) . In the present work, we observed this effect of CDK8/19 inhibition when NFκB was induced by the p21-independent canonical pathway inducers, TNFα and IL1, and noted that the effect of CDK8/19 inhibition on TNFα-induced NFκB-mediated transcription was undiminished by p21 knockout. In addition, a recent study reported that siRNA knockdown of both CDK8 and CDK19 in a myeloma cell line decreased the induction of several NFκB-inducible genes by a Toll-like receptor agonist (30) . Thus, CDK8/19 potentiate the transcriptional effects of NFκB induced by different signals.
The effects of CDK8/19 on NFκB-regulated genes were preferentially associated with genes showing a strong and early response to NFκB. Remarkably, in several cell lines of epithelial origin, the top CDK8/19-coregulated NFκB targets included a family of related cytokines with tumor-promoting and proinflammatory activities: IL8, CXCL1, and CXCL2. These cytokines, ligands of CXCR1/2 receptors, are known to play key roles in the interactions of tumor cells with various stromal components of the tumor microenvironment (31, 32) . In particular, the induction of chemoresistance and metastasis in breast cancer xenografts treated with doxorubicin and cyclophosphamide has been associated with TNFα-induced NFκB-mediated transcription of CXCL1/2 (20) . In a previous study, we found that doxorubicin treatment of mice promoted tumor engraftment and drug resistance in lung cancer xenograft models, effects that were suppressed by administration of the CDK8/19 inhibitor Senexin A, and identified IL8 as one of the damage-induced cytokines affected by Senexin A in HCT116 cells (3) . In both studies, it appears likely that cytokine induction through cooperation of damage-stimulated NFκB and CDK8/19 might have been responsible for the tumor-promoting effects of chemotherapy.
A survey of various types of tumor and normal cells regarding the effect of CDK8/19 inhibition on the induction of CXCL1, CXCL2, and IL8 by TNFα showed substantial heterogeneity among cell lines, with IL8 showing the most consistent response. Similar heterogeneity was seen in the effect of CDK8 shRNA in suppressing hypoxia-induced transcription of different genes in different cell lines (7); a heterogeneous response to various transcription factors and cofactors is a general feature of transcriptional regulation in eukaryotes. Importantly, CDK8/19 inhibition, while suppressing newly induced NFκB-driven transcription, in most cases had no effect on the ongoing expression of NFκB-regulated genes. The same selective regulation of newly induced but not already active transcription by CDK8/19 inhibition was seen here for IFNγ-and hypoxia-induced gene expression and in our previous study for estrogen receptor-regulated transcription (8) . This selective action of CDK8/19 identifies these kinases as mediators of transcriptional reprogramming, a key feature of development and differentiation as well as of pathological processes, most notably cancer. With this unique function, CDK8/19 inhibitors, some of which are now entering clinical trials, provide flexible tools for studying and modulating many important biological and pathological processes.
Materials and Methods
Sources of the reagents and antibodies and descriptions of all procedures are provided in SI Materials and Methods. Cell lines are described in Table S1 . Primers used for qPCR analysis are listed in Table S2 , and primers used for ChIP analysis are listed in Table S3 .
